Palatin signs up to €280M collaboration with Boehringer for retinal disease therapies

PALATIN TECHNOLOGIES INC

€2M upfront, up to €18M near-term milestones, up to €260M in regulatory/commercial milestones plus tiered royalties.
Collaboration focuses on melanocortin receptor agonists for diabetic retinopathy and DME; Boehringer funds two-year research.
Palatin assigned patent rights to Boehringer; potential first-in-class treatment targeting inflammation, vascular dysfunction, neurodegeneration.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.